Compounds > creatine ethyl ester
Page last updated: 2024-11-12

creatine ethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10197817
CHEMBL ID2398526
SCHEMBL ID672097
MeSH IDM0537707

Synonyms (17)

Synonym
AKOS006288081
CHEMBL2398526
creatine ethyl ester
15366-29-7
SCHEMBL672097
I3P1L0D47K ,
glycine, n-(aminoiminomethyl)-n-methyl-, ethyl ester
ethyl n-(aminoiminomethyl)-n-methylglycine
DTXSID70436615
unii-i3p1l0d47k
glycine,n-(aminoiminomethyl)-n-methyl-, ethyl ester
glycine,n-(aminoiminomethyl)-n-methyl-,ethyl ester
ethyl n-carbamimidoyl-n-methylglycinate
ethyl[[[amino](imino)methyl](methyl)amino]acetate
UFUWQSYRGLMLKP-UHFFFAOYSA-N
ethyl 2-[carbamimidoyl(methyl)amino]acetate
Q3501033

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Creatine dosing led to an improvement over the placebo condition on several measures."( Cognitive effects of creatine ethyl ester supplementation.
Kritikos, M; Ling, J; Tiplady, B, 2009)		0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID755485Drug uptake in rat primary cortical neuron lysate at 10 ug/mL after 1 hr by HPLC-MS/MS analysis relative to initial content2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755500Drug uptake in rat primary cortical neurons at 10 ug/mL after 1 hr by HPLC-MS/MS analysis relative to initial content2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755509Neurotoxicity against rat primary cortical neurons assessed as cell death at 10 ug/mL after 60 mins by LDH assay relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755516Induction of membrane disruption in rat astroglial/endothelial cells BBB model assessed as lucifer yellow permeability at 1 ug/mL after 60 mins by fluorescence assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755501Drug uptake in rat primary cortical neuron at 1 ug/mL after 1 hr by HPLC-MS/MS analysis relative to initial content2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755489Drug uptake in rat primary cortical neuron supernatant at 1 ug/mL after 1 hr by HPLC-MS/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755515Induction of membrane disruption in rat astroglial/endothelial cells BBB model assessed as lucifer yellow permeability at 10 ug/mL after 60 mins by fluorescence assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755512Cytotoxicity against rat endothelial cells assessed as cell viability at 10 ug/mL after 75 mins by MTT assay relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755505Lipophilicity, log p of the compound2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755487Drug uptake in rat primary cortical neuron supernatant at 10 ug/mL after 1 hr by HPLC-MS/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755511Cytotoxicity against rat astrocytes assessed as cell viability at 10 ug/mL after 75 mins by MTT assay relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755486Drug uptake in rat primary cortical neuron lysate assessed per mg of protein at 1 ug/mL after 1 hr by HPLC-MS/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755484Drug uptake in rat primary cortical neuron lysate assessed per mg of protein at 10 ug/mL after 1 hr by HPLC-MS/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
AID755508Neurotoxicity against rat primary cortical neurons assessed as cell death at 1 ug/mL after 60 mins by LDH assay relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (28.57)29.6817
2010's10 (71.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.98 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index112.92 (26.88)
Search Engine Supply Index3.98 (0.95)

This Compound (40.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (13.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies4 (26.67%)4.05%
Observational0 (0.00%)0.25%
Other9 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
creatine
[no description available]		6.88132glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.0810
Dyskinesia Syndromes
[description not available]		02.1710
Mental Retardation, X-Linked
A class of genetic disorders resulting in INTELLECTUAL DISABILITY that is associated either with mutations of GENES located on the X CHROMOSOME or aberrations in the structure of the X chromosome (SEX CHROMOSOME ABERRATIONS).		03.8921
Auditory Processing Disorder, Central
[description not available]		02.1710
Brain Diseases, Metabolic, Familial
[description not available]		02.1710
Movement Disorders
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.		02.1710
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		02.8130
Metabolic Acidosis
[description not available]		02.2110
Indigestion
[description not available]		02.2110
Acidosis
A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.		02.2110
Dyspepsia
Impaired digestion, especially after eating.		02.2110
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		02.8130
Amyotonia Congenita
[description not available]		04.3511
Neuromuscular Diseases
A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.		04.3511